INNOVENT - Technologieentwicklung Jena


Inhalt / content

Antibacterial coatings

Even in the modern medicine bacterial infections represent serious complications, which can influence the treatment and/or operation result and therefore endanger healing chances of the patients. Beyond that, the treatment of bacterial infections is complicated by increasing resistance features of the microorganisms against conventional antibiotics and is attended with substantial costs. Beside a systemic antibiotic gift, which is connected with the well-known disadvantages (undesireable side effects, training of resistances), more and more antiadhesive and/or antibacterial coatings are used for the prevention of infections as alternative and/or additional therapy. For that reason efforts in the development of permanently antibacterial working coatings are increasing at present.
Within the technology platform "J1013" (a confederation of 13 companies and 5 research institutes in the region of Jena) different concepts for coating of porcelain, yarn and textiles with tailor-made antimicrobial acting layers were developed.
The biological testing of antimicrobial properties of coated substrates will proceeded with different bacteria. The vitalities and adhesion behaviour will be measured after different times with cell biological testing methods.
Another project focuses on coatings based on cationic polymers, namely quarternary ammonium, phosphonium and tertiary sulfonium compunds. The antibacterial effect of the cationic polymers is based on interactions with the negatively charged cell membrane of bacteria, which lead to a destruction of the cytoplasmic membrane and therefore to the death of the bacterium. These polymers are synthesized by radical polymerization and covalently bound to a functionalized substrate. The coatings were tested successfully against gram positive bacteria, e.g. Staphylococcus aureus and Staphylococcus epidermidis and against the gram negative bacteria, e.g. Escherichia coli. In these tests an antibacterial effect of up to 97,3% could be achieved. The cytocompatibility of the coatings was proven in first in-vitro-tests based on a mouse fibroblast cell line.


Contact person:
Dr. Thorsten Laube
Dr. Claudia Rode

Unternavigation / subnavigation

Fusszeile /footer